Treatment of keloid scars with intralesional triamcinolone and 5-fluorouracil injections – a randomized controlled trial


      Keloids have high recurrence rates. Current first-line therapy is triamcinolone (TAC) injection, but it has been suggested that approximately 50% of keloids are steroid resistant. We compared the efficacy of intralesional 5-fluorouracil (5-FU) and triamcinalone injections in a double-blind randomized controlled trial. Forty-three patients with 50 keloid scars were treated with either intralesional TAC or 5-FU-injections over 6 months.
      There was no statistically significant difference in the remission rate at 6 months between the 5-FU and TAC groups (46% vs 60%, respectively). Local adverse effects were higher in the TAC group compared to the 5-FU group. Occurrence of skin atrophy in TAC group was 44% and in the 5-FU group 8% (p < 0.05). Also the occurrence of telangiectasia in the TAC group was 50% and in the 5-FU 21% (p < 0.05). Vascularity of the keloids, assessed by spectral imaging and immunohistochemical staining for blood vessels, after treatment decreased in the TAC group, but not in the 5-FU group (p < 0.05). Fibroblast proliferation evaluated by Ki-67 staining significantly decreased in the TAC group (p < 0.05) but increased in the 5-FU group (p < 0.05).
      TAC and 5-FU injections did not differ in their clinical effectivity in this randomized study, but 5-FU injections lead to increased proliferation rate and did not affect vascular density in histological assessment. Due to the greater number of adverse effects observed after TAC treatment, 5-FU injections may be preferable for cosmetically sensitive skin areas.


      To read this article in full you will need to make a payment


        • Al-Attar A
        • Mess S
        • Thomassen JM
        • et al.
        Keloid pathogenesis and treatment.
        J Plast Reconstr Surg. 2006; 117: 286-300
        • Chike-Obi CJ
        • Cole PD
        • Brisset AE
        Keloids: pathogenesis, clinical features, and management.
        Seminars Plast Surg. 2009; 23: 178-184
        • Hollander A.
        Intralesional injections of triamcinoloneacetonide: a therapy for dermatomes.
        Antibiot Med Clin Ther. 1961; 8: 78
        • Ketchum LD
        • Robinson DW
        • Masters FW
        Follow-up on treatment of hypertrophic scars and keloids with triamcinolone.
        J Plast Reconstr Surg. 1971; 48: 256-259
        • Murray RD
        Kenalog and the treatment of hypertrophied scars and keloids in negroes and whites.
        J Plast reconstr surg. 1963; 31: 275
        • Mustoe TA
        • Cooter RD
        • Gold MH
        International clinical recommendations on scar management.
        J Plast Reconstr Surg. 2002; 110: 560
        • Ud-Din S
        • Bowring A
        • Derbyshire B
        • Morris J
        • Bayat A
        Identification of steroid sensitive responders versus non-responders in the treatment of keloid disease.
        Arch Dermatol Res. 2013; 305: 423-432
        • Larrabee WF
        • East CA
        • Jaffe HS
        Intralesional interferon gamma treatment for keloids and hypertrophic scars.
        Arch Otolaryngol Head Neck surg. 1990; 116: 1159
        • Haurani MJ
        • Foreman K
        • Yang JJ
        • Siddiqui A
        5-fluorouracil treatment of problematic scars.
        J Plast Reconstr Surg. 2009; 123: 139-148
        • Bulstrode NW
        • Mudera V
        • McGrouther DA
        5-fluorouracil selectively inhibits collagen synthesis.
        J Plast Reconstr Surg. 2005; 116: 209
        • Sadeghinia A
        • Sadeghinia S
        Comparison of the efficacy of intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of keloids.
        Dermatol Surg. 2012; 38: 104-109
        • Srivastava S
        • Patil A
        • Prakash C
        • Kumari H
        Comparison of intralesional triamcinolone acetonide, 5-Fluorouracil, and their combination for the treatment of keloids.
        Adv Wound Care. 2017; 6: 11
        • Kaartinen IS
        • Valisuo PO
        • Alander JT
        • Kuokkanen HO
        Objective scar assessment–a new method using standardized digital imaging and spectral modelling.
        Burns. 2011; 37: 74-81
        • Kaartinen IS
        • Valisuo PO
        • Bochko V
        • Alander JT
        • Kuokkanen HO
        How to assess scar hypertrophy-a comparison of subjective scales and Spectrocutometry: a new objective method.
        WRR. 2011; 19: 316-323
        • May U
        • Prince S
        • Vähätupa M
        • et al.
        Resistance of R-Ras knockout mice to skin tumour induction.
        Sci Rep. 2015; 5: 11663
        • Vähätupa M
        • Aittomäki S
        • Martinex
        • et al.
        T-cell-expressed proprotein convertase FURIN inhibits DMBA/TPA-induced skin cancer development.
        OncoImmunology. 2016; 51245266
        • Järvinen TA
        • Ruoslahti E
        Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice.
        Proc Natl Acad Sci USA. 2010; 107: 21671-21676
        • Nanda S
        • Reddy BS
        Intralesional 5-fluorouracil as a treatment modality of keloids.
        Dermatol Surg. 2004; 30: 54-56
        • Kontochristopoulos G
        • Stefanaki C
        • Panagiotopoulos
        • et al.
        Intralesional 5-fluorouracil in the treatment of keloids: an open clinical and histopathologic study.
        J Am Acad Dermatol. 2005; 3: 474-479
        • Ogawa R
        The most current algorithms for the treatment and prevention of hypertrophic scars and keloids.
        J Plast Reconstr Surg. 2010; 125: 557-568
        • Hietanen K
        • Välisuo P
        • Kuokkanen H
        • Kaartinen I
        Long-term results of intralesional triamcinolone acetonide injections in keloid treatment.
        J Clin Trials. 2016; 6: 4
        • Fitzpatrick RE
        Treatment of inflamed hypertrophic scars using intralesional 5-FU.
        Dermatol Surg. 1999; 25: 224-232
        • Manuskiatti W
        • Fitzpatrik RE
        • Goldman MP
        Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser.
        J Am Acad Dermatol. 2001; 45: 557-565
        • Chan HH
        • Wong DSY
        • Ho WS
        The use of pulsed dye laser for prevention and treatment of hypertrophic scars in Chinese persons.
        Dermatol Surg. 2004; 30: 987-994
        • Hochman B
        • Locali RF
        • Matsuoka PK
        Intralesional triamcinolone acetonide for keloid treatment: a systematic review.
        Aesth Plast Surg. 2008; 32: 705-709
        • Leventhal D
        • Furr M
        • Reiter D
        Treatment of keloids and hypertrophic scars.
        Arch Facial Plast Surg. 2006; 8: 362-368